Cargando…
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
BACKGROUND: Aripiprazole is a third-generation antipsychotic agent with acceptable efficacy and a good safety profile. Previous studies have indicated the therapeutic serum concentration of aripiprazole to be 100 to 350 ng/ml; however, most of these studies examined a Western population. Patients wi...
Autores principales: | Tien, Yun, Huang, Hsiang-Ping, Liao, Ding-Lieh, Huang, Shang-Chien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340887/ https://www.ncbi.nlm.nih.gov/pubmed/35923249 http://dx.doi.org/10.1177/20451253221113238 |
Ejemplares similares
-
Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021) -
Treatment of refractory catatonic schizophrenia with low dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2012) -
Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study
por: Hsu, Yi-Chien, et al.
Publicado: (2015) -
Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qian, Li, et al.
Publicado: (2021) -
Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)